Morria Biopharmaceuticals Plc Announces The Initiation Of A Phase Ii Clinical Multi-dose Study Of Mr 25th June 2008 - Views: 1430 Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, today announced that it has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi- dose, double-blind, placebo-controlled study includes Rhinocort(R) as the steroid comparator arm.
Polymerase Chain Reaction - An Analytical Report, 2009-2015 25th January 2011 - Views: 5069 The latest PCR market trends with a perceptive attempt to disclose the near-future growth prospects and an in-depth analysis on a geographic basis provide strategic business intelligence.
Changzhou To Develop Bio-pharmaceutical Incubator 28th January 2010 - Views: 1569 On January 16, a foundation laying ceremony for the Changzhou Bio-pharmaceutical Incubator -- an innovative technological medium with international standards, with Changzhou Fangyuan Pharmaceutical Co., Ltd.
Clinical Data Presented At Asia Pcr/sing Live Demonstrate Benefits Of Orbusneich's Genoust Bio-engi 2nd February 2010 - Views: 1129 OrbusNeich announced that clinical data presented at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.
Herceptin Now Approved In The Eu For Patients With Her2-positive Advanced Stomach Cancer 28th January 2010 - Views: 1521 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer.